Table 2.
Summary of patient samples (ascites, plasma, CVS) used for comparison of active CXCL10 ratios between benign and malignant samples *.
| Group | Pathology | Grade | Stage | Median CA125 (IQR) | Menopausal Status |
|---|---|---|---|---|---|
| Benign (n = 51) |
Cystadenoma (n = 19) Fibroma (n = 10) Other (n = 22) |
n/a | n/a | 52 (23–154) | Mixed |
| Malignant (n = 224) |
Serous (n = 163) Mucinous (n = 10) Endometroid (n = 14) Clear cell (13) Mixed epithelial/poorly differentiated (n = 24) |
1–3 | I–IV | 641 (149–1591) | Mixed |
* See Supplementary Table S1 for individual details.